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in 7313 children from a UK birth cohort, 
eliminating concerns of population strati-
fication (St Pourcain et al., 2010).
Like McClellan and King, we expect 
that with the development of high-
throughput sequencing technologies, 
whole-genome sequencing will be an 
invaluable tool for the study of rare 
genetic variants contributing to com-
plex diseases. However, the apparent 
importance of rare variants does not 
discount the contribution of common 
variants; the concerns about population 
stratification should not be overstated 
and certainly should not be presented 
as an argument to discredit many pub-
lished GWAS signals with an odds ratio 
of less than 2. These sections within 
an otherwise excellent Essay must be 
countered so that Cell readers have a 
more balanced view of the current state 
of the field.
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In response to our Essay “Genetic Het-
erogeneity of Human Disease” (McClellan 
and King, 2010), Wang et al. and Klein et al. 
challenge our critique of GWAS findings. 
Both Correspondence suggest that our 
conclusions lack an understanding of the 
principles of the common variant-common 
disease model and its application in GWAS 
methodology. We respectfully disagree, 
and in fact our Essay directly addressed 
many of their points. We are happy to clar-
ify further. The issue is not ignorance of 
GWAS methodology; the issue is reconcil-
ing GWAS findings with population genet-
ics, evolution, and biology.
There is no dispute that common 
genetic variants influence human traits. 
Alleles with the strongest influences on 
human traits are associated with benign 
phenotypes, such as hair color and 
eye color, that vary across individuals. 
Alleles for these traits lie in coding and 
known regulatory regions (Hindorff et 
al., 2009). Such variants have been influ-
enced by selection in human evolution. 
Thus, the best documented common 
variants with a substantial impact on 
disease risk typically are associated with 
illnesses presenting later in life, includ-
ing Alzheimer’s disease (APOE), exfoliat-
ing glaucoma (LOXL1), and age-related 
macular degeneration (CFH). These 
alleles persist in the population because 
the associated illnesses do not nega-
tively influence reproductive fitness.
However, the existence of common 
alleles that truly influence disease does 
not imply that all GWAS findings are 
valid. To date, published GWAS have 
reported more than 500 single-nucle-
otide polymorphisms (SNPs) associated 
with various diseases and traits, 88% of 
which lie in introns or intergenic regions, 
and for which the median odds ratio for 
effect size is 1.33 (Hindorff et al., 2009). 
Few of these associations have biologi-
cal support.
In order to identify alleles that influence 
disease using GWAS, two fundamen-
tal criteria must be met: (1) a common 
variant influencing the trait in question 
must truly exist in the population being 
studied; and (2) the genotyped markers 
used in association analyses must either 
include the causal variant or be in link-
age disequilibrium (LD) with the causal 
variant in the population being stud-
ied. Common “risk SNPs” detected by 
GWAS could in theory be in LD with rare 
disease-causing alleles, if by chance 
rare causal alleles are disproportionately 
linked with a common variant (Dickson et 
al., 2010).
In addressing our critique, both 
Wang et al. and Klein et al. acknowl-
edge that GWAS methodologies are 
designed to detect SNPs primarily 
found in intergenic or intronic regions, 
given the construction of standard SNP 
arrays. They argue that the risk SNPs 
implicated by GWAS are not expected 
to be causal but instead are in LD with 
true causal variants. Wang et al. main-
tain that standard GWAS methodolo-
gies adequately control for population 
stratification. Further, they note that 
a large proportion of HapMap SNPs 
vary widely across populations, and 
therefore it is not surprising that highly 
variable SNPs emerge as risk vari-
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ants. These issues are at the crux of 
the debate and will be the focus of our 
response.
Genetic heterogeneity across human 
populations limits GWAS methodology 
and may result in the identification of “risk 
alleles” that are neither likely to be func-
tional nor likely to be in LD with alleles that 
are. The genetic architecture of human 
disease is shaped by the same evolu-
tionary forces that impact the human 
genome. Genetic architecture is dic-
tated by four factors: mutation, selection, 
migration, and drift. Negative selection 
globally reduces variation at missense 
mutations, particularly in genes associ-
ated with disease (Barreiro et al., 2008). 
Frequencies of missense alleles (i.e., 
nonsynonymous SNPs) are less diverse 
across populations than are frequencies 
of synonymous SNPs, SNPs in untrans-
lated regions (UTRs), and intronic SNPs 
because selection reduces interpopula-
tion variation for alleles influencing phe-
notypic expression (Garte, 2010). Popula-
tion differences in genic regions, primarily 
at nonsynonymous SNPs and 5`UTR vari-
ants, may persist as the result of selec-
tion for adaptive responses or by chance 
(Barreiro et al., 2008). For alleles influ-
encing phenotypes, selection constrains 
overall variation in allele frequency while 
also influencing specific patterns of varia-
tion defined by geographic ancestry.
Many SNPs, inversions/deletions 
(indels), and short tandem repeats 
vary widely in allele frequency among 
populations.  This is especially true for 
variants that are not in coding or regu-
latory regions.  Such alleles vary with 
population clusters in patterns more 
consistent with neutral drift and migra-
tion rather than with selection (Coop et 
al., 2009). The colonization of the world 
by modern humans was carried out 
by a series of founder populations with 
subsequent rapid expansion of popula-
tion size. Neutral alleles emerging at the 
forefront of these expansions “surfed” 
waves of population growth. Variations 
in allele frequencies across populations 
stem from differences in the timing of the 
variant’s emergence in the expansion.
Intergenic or intronic SNPs that vary 
widely in frequency among populations 
are most likely neutral alleles reflect-
ing the history of human migration. 
Wide variations in allele frequency also 
characterize many “risk alleles” identi-
fied by GWAS, including, for example, 
rs4307059 reported to be associated 
with autism (Wang et al., 2009), which is 
a major focus of the Correspondence by 
Wang et al. We suggest that associations 
based on such highly variable SNPs are 
often artifacts of cryptic population strat-
ification. Wang et al. argue that standard 
GWAS strategies have been adopted to 
control for population stratification. How-
ever, these methods control by person, 
not by SNP. Because populations from 
large geographic areas (e.g., Europe) are 
genetically heterogeneous, outlier SNPs 
that vary widely among subgroups of 
such populations are not excluded by 
these methods and often drive positive 
associations.
Wang et al. also assert that the asso-
ciation of rs4307059 and autism was 
driven by family-based cohorts, which 
are robust to stratification. However, 
no SNPs reached genome-wide signifi-
cance in their study using a family-based 
design (Wang et al., 2009). Significance 
was obtained by pooling subjects from 
both family-based and case-control 
samples, including thousands of unre-
lated cases and controls. Analyses 
only comparing affected to unaffected 
persons within families will be robust 
to stratification; but comparing a mixed 
series of related and unrelated cases to 
controls can exacerbate stratification 
due to the clustering of shared ances-
tries in the affected group.
In arguing for rs4037059 as a risk vari-
ant for autism, Wang et al. dismiss the 
negative results of a replication study 
(Weiss et al., 2009) due to small sample 
size. Yet, they cite another study (Ma et al., 
2009) as supporting an association with 
this genomic region (5p14.1), even though 
no SNPs in this study met genome-wide 
significance and rs4037059 was not even 
nominally significant in the discovery 
sample. Variable weak associations of 
different SNPs across the same genomic 
region in different cohorts do not consti-
tute replication.
Both Klein et al. and Wang et al. suggest 
that the vast majority of GWAS risk alleles 
are in LD with causal mutations, and that 
intergenic and intronic risk variants rep-
resent regulatory elements. In principle, 
either or both of these hypotheses could 
be true. However, thus far, virtually no 
such mutations or elements have been 
found by following up on GWAS findings. 
Wide variations in allele frequency across 
populations argue against shared hap-
lotype structure, which is necessary to 
detect causal variants in LD.
Common variants influencing traits or 
disease must withstand selection in every 
generation in order to be maintained at 
polymorphic frequencies worldwide. 
Regulatory elements are impacted by 
the same evolutionary forces as coding 
regions. Klein et al. discuss alternative 
methods whereby otherwise deleterious 
alleles are maintained in the population, 
citing both well-known and speculative 
examples of balancing selection and 
gene-environment interactions. How-
ever, as is the case for much of this dis-
cussion, a confirmed biological mecha-
nism for one illness does not mean that 
all GWAS findings can be attributed to 
similar mechanisms.
Klein et al. suggest that a common 
risk allele may have been under neu-
tral or positive selection in early human 
history, thus explaining its worldwide 
prevalence and maintenance in the 
population despite the association with 
disease. Yet evolution is an ongoing 
process. If a common variant decreases 
reproductive fitness during modern his-
tory, coinciding with the vast expansion 
of the human population, the frequency 
of the variant will decline. Klein et al. 
also suggest that many common risk 
variants, either the identified SNP or 
a causal variant in LD, operate by vir-
tue of some yet-to-be-determined bal-
ancing selection or gene-environment 
interaction. This is obviously possible 
but needs to be demonstrated for any 
given variant. In the presence of a true 
balancing selection or gene-environ-
ment interaction, variation in allele fre-
quencies will correlate with geographic 
variation in disease prevalence and is 
likely to offer clues about specific envi-
ronmental exposures or risk factors. 
The best characterized examples of 
balancing selection are found in spe-
cific geographic populations sharing 
an environmental exposure, such as an 
infectious disease. In these examples, 
e.g., sickle cell disease, risk alleles are 
maintained at a much higher rate in the 
exposed population than in populations 
from other parts of the world.
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It is a leap of theoretical faith to infer that 
SNPs with no known function and variable 
weak associations across different disease 
cohorts represent prima facie evidence of 
regulatory function, gene-environment 
interaction, or balanced selection. We are 
not suggesting that such phenomena do 
not occur. Deciphering such mechanisms 
will be a major scientific focus over the next 
decade. However, for the vast majority of 
SNPs identified by GWAS, these mecha-
nisms are speculative in the absence of 
biological evidence.
Many of the examples cited by Klein et 
al. and Wang et al. in support of GWAS 
suffer from the same limitations that we 
highlighted in our Essay (McClellan and 
King, 2010). For example, as Klein et al. 
describe, there is robust epidemiologi-
cal data in support of individuals with 
diabetes having a lower risk for prostate 
cancer. However, associations between 
putative risk/protective SNPs in HNF1B 
and JAZF1 and the two illnesses vary 
across cohorts, and these variants do 
not mediate the relationship between the 
two diseases (Stevens et al., 2010).
We understand that many believe that 
most GWAS findings are valid. Ultimately, 
the debate hinges on how definitive one 
views variable results with statistically 
highly significant p values and very small 
effects that diminish with further study. 
Currently, GWAS results fail to explain 
the vast majority of genetic influence 
on any human illness. Further, most risk 
variants implicated by GWAS have no 
demonstrated biological, functional, or 
clinical relevance for disease.
We suggest that biological relevance 
needs to be established before assert-
ing that positive correlations from GWAS 
are equivalent to disease risk. Such evi-
dence must address the functional sig-
nificance of the SNP, or a variant in LD 
with the SNP, rather than arguing for the 
appeal of a nearby gene. In their argu-
ments, Wang et al. and Klein et al. simply 
restate GWAS principles, which serves 
to reify, not prove, the model. We make a 
plea for more rigorous analysis. Science 
ultimately advances by evidence.
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